Biblio

Author Title Type [ Year

]

Filters: Author is Popat, Uday [Clear All Filters]

2019

Ciurea, S.O., Hansrivijit, P., Ciurea, A.M., Hymes, S., Chen, J., Rondon, G., Hosing, C., Popat, U., and Champlin, R.E. (2019). Curative Potential of Hematopoietic Stem Cell Transplantation for Advanced Psoriasis.Am J Hematol.

Srour, S.A., Saliba, R.M., Bittencourt, M.Cb, Perez, J.Miguel Ram, Kongtim, P., Alousi, A., Al-Atrash, G., Olson, A., Betul, O., Mehta, R., et al. (2019). Haploidentical Transplantation for Acute Myeloid Leukemia Patients with Minimal/ Measurable Residual Disease at Transplantation.Am J Hematol.

Saini, N.Y., Saliba, R.M., Rondon, G., Maadani, F., Popat, U., Hosing, C.M., Betul, O., Bashir, Q., Olson, A., Nieto, Y., et al. (2019). Impact of Donor Type and Melphalan Dose on Allogeneic Transplant Outcomes for Patients with Lymphoma.Biol Blood Marrow Transplant.

Kongtim, P., Hasan, O., Perez, J.Miguel Ram, Varma, A., Wang, S.A., Patel, K.P., Chen, J., Rondon, G., Srour, S., Bashir, Q., et al. (2019). A Novel Disease Risk Model for Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant.

2018

Veltri, L., Rezvani, K., Oran, B., Mehta, R., Rondon, G., Kebriaei, P., Popat, U., Nieto, Y., Hosing, C., Qazilbash, M., et al. (2018). Allotransplants for patients 65 years or older with high-risk acute myeloid leukemia.Biol Blood Marrow Transplant.

Valdez, B.C., Tang, X., Li, Y., Murray, D., Liu, Y., Popat, U., Champlin, R.E., and Andersson, B.S. (2018). Epigenetic modification enhances the cytotoxicity of busulfan and 4-hydroperoxycyclophosphamide in AML cells.Exp Hematol.

Afrough, A., Saliba, R.M., Hamdi, A., Honhar, M., Varma, A., A Cornelison, M., Rondon, G., Parmar, S., Shah, N.D., Bashir, Q., et al. (2018). Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation.Biol Blood Marrow Transplant.

Radivoyevitch, T., Dean, R.M., Shaw, B.E., Brazauskas, R., Tecca, H.R., Molenaar, R.J., Battiwalla, M., Savani, B.N., Flowers, M.E.D., Cooke, K.R., et al. (2018). Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma.Leuk Res.

2016

Ustun, C., Gotlib, J., Popat, U., Artz, A., Litzow, M., Reiter, A., Nakamura, R., Kluin-Nelemans, H.C., Verstovsek, S., Gajewski, J., et al. (2016). Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis.Biol Blood Marrow Transplant.

Nieto, Y., Valdez, B.C., Thall, P.F., Jones, R.B., Wei, W., Myers, A., Hosing, C., Ahmed, S., Popat, U., Shpall, E.J., et al. (2016). Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.Cancer.

Gaballa, S., Saliba, R.M., Srour, S., Lu, G., Brammer, J.E., Shah, N., Bashir, Q., Patel, K., Bock, F., Parmar, S., et al. (2016). Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant.Am J Hematol.

Kebriaei, P., Singh, H., M Huls, H., Figliola, M.J., Bassett, R., Olivares, S., Jena, B., Dawson, M.J., Kumaresan, P.R., Su, S., et al. (2016). Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.J Clin Invest.

Aung, F.M., Lichtiger, B., Rondon, G., C Yin, C., Alousi, A., Ahmed, S., Andersson, B., Bashier, Q., Ciurea, S.O., Hosing, C., et al. (2016). Pure Red Cell Aplasia in Major ABO Mismatched Allogeneic Hematopoietic Stem Cell Transplantation is Associated with Severe Pancytopenia.Biol Blood Marrow Transplant.

Gaballa, S., Ge, I., Fakih, R.El, Brammer, J.E., Kongtim, P., Tomuleasa, C., Wang, S.A., Lee, D., Petropoulos, D., Cao, K., et al. (2016). Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.Cancer.

2015

Nieto, Y., Valdez, B.C., Thall, P.F., Ahmed, S., Jones, R.B., Hosing, C., Popat, U., Shpall, E.J., Qazilbash, M., Gulbis, A., et al. (2015). Vorinostat Combined with High-Dose Gemcitabine, Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphomas.Biol Blood Marrow Transplant.

2014

Nash, R.A., Hutton, G.J., Racke, M.K., Popat, U., Devine, S.M., Griffith, L.M., Muraro, P.A., Openshaw, H., Sayre, P.H., Stüve, O., et al. (2014). High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS): A 3-Year Interim Report.Jama Neurol.

2013

Poon, L.Michelle, Di Stasi, A., Popat, U., Champlin, R.E., and Ciurea, S.O. (2013). Romiplostim for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation.Am J Blood Res3, 260-4.